查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830999

單核細胞活化測試市場

Monocyte Activation Tests Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

2024 年單核細胞活化測試市值為 8,957 萬美元，預計到 2031 年將達到 2.8448 億美元，2025 年至 2031 年的複合年成長率預計為 17.5%。

分析師的觀點

單核細胞活化檢測市場分析突顯了關鍵促進因素，例如患者日益成長的安全擔憂，以及製藥、生物技術和醫療器材等行業對更安全的熱原檢測方法的需求日益成長。此外，單核細胞活化檢測方法相關技術的進步預計將在整個預測期內推動市場成長。

依來源分類，單核細胞活化測試市場分為PMBC和細胞株兩類。 PMBC細分市場在2022年佔據了較大的市場佔有率，預計在預測期內將保持這一趨勢。就產品而言，市場分為MAT試劑盒和試劑，其中MAT試劑盒細分市場在2022年也佔據了較大的佔有率，預計這一趨勢將持續下去。相反，預計試劑細分市場在預測期內將經歷更高的複合年成長率。市場已按應用進一步細分為藥物開發、疫苗開發、醫療器材和其他（例如研究）領域。藥物開發細分市場在2022年佔據了最大的佔有率，預計在2022年至2030年期間將保持這一趨勢。

單核細胞活化試驗 (MAT) 可識別由於內毒素和非內毒素熱原共同作用而導致的細胞激素釋放增強。 MAT 是一種體外檢測方法，旨在評估腸外給藥、生物製劑和醫療器材中所有類型熱原的含量。在過去五年中，先前依賴兔熱原試驗進行釋放檢測的疫苗已率先採用單核細胞活化試驗 (MAT)。與 MAT 不同，細菌內毒素檢測通常不適用於本身俱有熱原性或含有疫苗中常見添加劑（例如氫氧化鋁）的產品，因為這些添加劑會干擾檢測。 MAT 在疫苗檢測中的應用範例包括腦膜炎奈瑟菌疫苗、高免血清、腦膜炎雙球菌疫苗、黃熱病疫苗、宋內志賀氏菌疫苗、狂犬病疫苗、B型肝炎疫苗和蜱傳腦炎病毒疫苗。

戰略洞察

市場洞察

醫療器材產業需求不斷成長

單核細胞活化試驗 (MAT) 是一種基於人類細胞的檢測方法，用於檢測和量化細菌、真菌和病毒等熱原。 MAT 採用 ELISA 檢測來測量處理後的血球釋放的細胞激素。儘管 MAT 廣泛可用，但在評估醫療器材的生物相容性時，它們很少用作基於動物的熱原試驗的替代品。 2018 年 9 月，美國國家毒理學計劃替代毒理學方法評估跨部門中心 (NICEATM) 和 PETA 國際科學聯盟有限公司 (PISC) 在美國國立衛生研究院舉辦了一場研討會，討論在醫療器材測試中實施 MAT 的必要步驟。據 DXC Technology Company 旗下公司 Luxoft 稱，醫療器材透過預測演算法和患者資料分析實現準確的診斷、有效的治療和個人化護理，從而促進醫療保健的數位轉型。個人化醫療、植入式設備、智慧醫療設備和非侵入性手術領域的創新正在改變醫療保健格局，提供更優質的照護、更佳的患者預後並降低成本。醫療器材產業的成長反過來又推動了單核細胞活化檢測方法的擴展，預計在預測期內這一趨勢將持續下去。

市場機會單核細胞活化測試方法的技術進步

單核細胞活化試驗方法最初是作為動物試驗的替代方案引入，旨在提供在人體體外環境中進行熱原檢測的機會。單核細胞活化試驗 (MAT) 於 2010 年在國際驗證出版物發布後被納入歐洲藥典 (EP)。市場參與者不斷創新和改進 MAT 檢測方法和試劑，顯著提高了重現性、靈敏度和特異性，使其成為可靠且更安全的熱原檢測選擇。 MAT 檢測方法用於鑑定腸外產品（包括藥品和醫療器材）中的內毒素和非內毒素熱原。通常，MAT 可作為傳統動物試驗的體外替代方案，符合監管指南的要求。兔熱原檢測和鱟試劑 (LAL) 檢測是熱原檢測的常用方法，但這兩種方法都涉及動物實驗，且有一定的限制。兔熱原檢測缺乏穩定性，因為動物反應可能與人類反應不同。此外，LAL 檢測僅檢測內毒素，會忽略樣本中可能存在的非內毒素熱原，從而帶來安全風險。為了解決這些局限性，單核細胞活化試驗 (MAT) 於 2010 年被納入《歐洲藥典》，作為替代兔熱原檢測法（歐洲藥典第 2.6.30 章）的藥典方法，並被納入 FDA 行業指南。市場參與者不斷創新和開發 MAT 檢測方法和試劑，從而提高了重現性、靈敏度和特異性，使其成為一種可靠且更安全的熱原檢測方法。

報告細分和範圍基於來源的洞察

依來源分類，單核細胞活化測試市場分為周邊血單核細胞（PMBC）和細胞株兩類。 PMBC 細分市場在 2022 年佔據了較大的市場佔有率，預計在預測期內將保持這一趨勢，並預計 2022 年至 2030 年的複合年成長率更高。目前，全球有兩種商業化的單核細胞活化測試細胞來源：Mono-Mac-6 (MM6)細胞株和周邊血單核細胞 (PBMC)。 MM6細胞株來自單一急性單核細胞白血病患者的血液，這可能導致單核細胞無法像健康人一樣持續表達檢測致熱原污染物和觸發細胞因子釋放所必需的 TLR。因此，使用此細胞來源的 MAT 結果的可重複性較低。歐洲藥典 (2.6.30) 也規定，基於 MM6 的 MAT 試劑盒檢測非內毒素致熱原的能力「有限」。相較之下，基於PBMC的MAT試劑盒採用來自已篩選健康捐贈者的混合血的PBMC，從而能夠更準確地模擬與加標產品樣本孵育時的人類單核細胞活化。因此，基於此細胞來源的MAT試劑盒始終表現出可重複的結果。歐洲藥典(2.6.30)認可此細胞來源能夠高效檢測內毒素和非內毒素熱原。

目前，市場上還有另外三家基於PBMC的商業化單核細胞活化檢測供應商，其檢測極限 (LoD) 分別為0.125 EU/ml、0.02 EU/ml和0.016 EU/ml。 CTL-MAT檢測的LoD為0.004 EU/ml，處於市場領先水平，是全球靈敏度最高的單核細胞活化檢測之一。

基於產品的洞察就產品而言，單核細胞活化測試市場分為 MAT 試劑盒和試劑。 MAT 試劑盒細分市場在 2022 年佔據了較大的市場佔有率，預計在預測期內將延續這一趨勢；而試劑細分市場預計在預測期內將經歷更高的複合年成長率。

基於應用的洞察按應用，單核細胞活化測試市場分為藥物開發、疫苗開發、醫療器材和其他（如研究）。藥物開發領域在 2022 年佔據了最大佔有率，預計從 2022 年到 2030 年將保持這一趨勢。根據美國國家醫學圖書館的數據，藥品是一類新興的有機化合物，可顯著改善患者的生活品質。製藥業參與品牌藥和學名藥的生產、開發和行銷。 2014 年全球醫藥收入首次超過 1 兆美元。自 2017 年以來，醫藥市場一直以每年 5.8% 的速度成長，2017 年全球醫藥市場收入達到 11,430 億美元，2021 年達到 14,620 億美元。單核細胞活化測試（MAT）旨在評估腸外藥物、生物製劑和醫療器材的所有類別的熱原。腸外給藥的藥品必須不含致熱原（引起發燒）污染，因為這些物質可能在患者的先天免疫系統中引發危及生命的全身反應。確保生物製品在給予患者前不含污染性的致熱原物質至關重要。最初，兔熱原試驗 (RPT) 和細菌內毒素試驗 (BET)/鱟試劑 (LAL) 被用作離體實驗。

然而，嚴格的動物試驗方法法規迫使市場參與者開發替代方法，以最大限度地減少動物使用。鑑於RPT和BET的局限性，以及複雜產品產量的不斷增加，歐洲藥典引入了MAT活化測試方法，該方法模擬人體免疫反應，並結合了RPT（評估革蘭氏陰性內毒素以外的致熱原性）和體外方法的優勢。與RPT不同，MAT可以作為完全定量的測試，無需使用動物，這使得它更適用於固有致熱原疫苗，並且由於其利用的是人體細胞，因此具有生理相關性。 MAT檢測方法可以檢測血液衍生產品、細胞衍生產品、生物製劑和疫苗。 MAT檢測方法還可以評估各種藥品和醫療器械，包括無法進行體內測試的產品（例如，含有透明質酸的產品）。這些因素促進了近年來單核細胞活化測試市場的整體成長，預計在預測期內將繼續保持這一趨勢。

單核細胞活化測試市場報告範圍區域分析

從區域來看，單核細胞活化測試市場細分為北美、歐洲、亞太地區、南美和中美以及中東和非洲。北美在2022年佔據最大市場佔有率，預計在預測期內將保持這一趨勢，其次是歐洲。美國藥典 (USP) 和加拿大政府等機構對單核細胞活化測試的監管實踐進一步刺激了該地區單核細胞活化測試市場的整體成長。此外，對病患安全和醫療效果改善的日益關注也促進了北美市場的成長。

單核細胞活化測試市場的領先公司包括德國達姆施塔特默克公司和/或其附屬公司、Charles River Laboratories International, Inc.、賽默飛世爾科技、Sanquin 和龍沙集團。

2023年10月，龍沙推出了兩款新的快速單核細胞活化檢測 (MAT) 系統：PyroCell MAT 快速系統和 PyroCell MAT 人類血清 (HS) 快速系統，旨在簡化和加速兔無熱原檢測。這些系統將取代龍沙傳統的 MAT 系統試劑盒產品。新推出的產品採用了全新的 PeliKine 人類 IL-6 快速 ELISA 試劑盒，可減少手動操作時間，並將結果獲取時間從兩天縮短至兩小時。新的檢測方法為製藥和生物技術製造商提供了更方便的 MAT 檢測選項，用於產品安全測試，同時有助於減少對動物測試的依賴。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：單核球活化測試市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：單核球活化測試市場-關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：單核球活化測試市場-全球市場分析

  • 單核細胞活化測試 - 全球市場概覽
  • 單核細胞活化測試－全球市場及2030年預測

第 7 章：單核細胞活化測試市場 - 收入分析 - 按來源，2020-2030 年

  • 概述
  • 前胸腔外科委員會
  • 細胞株

第 8 章：單核球活化測試市場 - 收入分析 - 按產品，2020-2030 年

  • 概述
  • MAT 套件
  • 試劑

第 9 章：單核細胞活化測試市場 - 收入分析 - 按應用，2020-2030 年

  • 概述
  • 藥物開發
  • 疫苗研發
  • 醫療器材
  • 其他（研究等）

第 10 章：單核細胞活化測試市場 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：新冠疫情前後的影響

第 12 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 13 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 14 章：單核細胞活化測試市場 - 主要公司簡介

  • Merck KGaA, Darmstadt,Germany and/or its Affiliates
  • Charles River Laboratories International, Inc.
  • Thermo Fisher Scientific
  • Sanquin
  • Lonza Group
  • MAT Biotech
  • Cellmade Laboratories
  • Labor LS SE & Co. KG
  • BD Biosciences
  • Beckman Coulter

第 15 章：附錄

簡介目錄
Product Code: TIPRE00004912

The monocyte activation tests market was valued at US$ 89.57 million in 2024 and is projected to reach US$ 284.48 million by 2031, with an estimated CAGR of 17.5% from 2025 to 2031.

Analyst's Perspective

The analysis of the monocyte activation tests market highlights key drivers such as increasing safety concerns among patients and a growing demand for safer pyrogen testing methods in industries like pharmaceuticals, biotechnology, and medical devices. Additionally, advancements in technology related to monocyte activation test methods are expected to drive market growth throughout the forecast period.

By source, the monocyte activation tests market is divided into PMBC and cell line categories. The PMBC segment held a larger market share in 2022 and is anticipated to maintain this trend during the forecast period. In terms of products, the market is categorized into MAT kits and reagents, with the MAT kits segment also holding a larger share in 2022 and expected to continue this trend. Conversely, the reagents segment is projected to experience a higher CAGR during the forecast period. The market is further segmented by application into drug development, vaccine development, medical devices, and others (such as research). The drug development segment accounted for the largest share in 2022 and is expected to maintain this trend from 2022 to 2030.

The monocyte activation test identifies enhanced cytokine release due to the combined effects of endotoxin and non-endotoxin pyrogens. The MAT is an in-vitro assay designed to evaluate parenteral drugs, biologics, and medical devices for all types of pyrogens. Over the past five years, vaccines that previously relied on the Rabbit Pyrogen Test for release assays have been among the first to adopt the monocyte activation test (MAT). Unlike MAT, bacterial endotoxin tests are often inadequate for products that are inherently pyrogenic or contain additives commonly found in vaccines, such as aluminum hydroxide, which can interfere with the assay. Examples of MAT's application in vaccine testing include the Neisseria meningitidis vaccine, Hyperimmune Sera, Meningococcal vaccines, Yellow fever vaccine, Shigella sonnei vaccine, Rabies vaccine, Hepatitis B Vaccine, and Tick-borne encephalitis virus vaccine.

Strategic Insights

Market Insights

Increasing Demand from the Medical Device Sector

Monocyte activation tests (MATs) are human cell-based assays used to detect and quantify pyrogens such as bacteria, fungi, and viruses. MATs employ an ELISA assay to measure cytokine release from treated blood cells. Although MATs are widely available, they are seldom used as substitutes for animal-based pyrogen tests in assessing the biocompatibility of medical devices. In September 2018, the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and the PETA International Science Consortium Ltd. (PISC) held a workshop at the National Institutes of Health to discuss the necessary steps for implementing MAT in medical device testing. According to Luxoft, a DXC Technology Company, medical devices are facilitating the digital transformation of healthcare by enabling accurate diagnoses, effective treatments, and personalized care through predictive algorithms and patient data analysis. Innovations in personalized medicine, implantable devices, smart medical devices, and non-invasive surgery are transforming the healthcare landscape by providing better care, improved patient outcomes, and reduced costs. The growth of the medical device industry has, in turn, supported the expansion of monocyte activation test methods and is expected to continue this trend during the forecast period.

Market Opportunity

Technological Advancements in Monocyte Activation Test Methods

Monocyte activation test methods were primarily introduced as alternatives to animal-based testing, providing the opportunity to conduct pyrogen testing in a human in vitro environment. The Monocyte Activation Test (MAT) was incorporated into the European Pharmacopeia (EP) in 2010 following international validation publications. Ongoing innovations and advancements in MAT assays and reagents by market players have significantly improved reproducibility, sensitivity, and specificity, making it a reliable and safer choice for pyrogen detection. The MAT assay is utilized to identify both endotoxins and non-endotoxin pyrogens in parenteral products, including pharmaceuticals and medical devices. Typically, the MAT serves as an in vitro alternative to traditional animal testing in compliance with regulatory guidelines. The Rabbit Pyrogen Test and the Limulus Amebocyte Lysate (LAL) test are commonly used for pyrogen detection, but both methods involve animal use and have certain limitations. The rabbit pyrogen test lacks robustness, as animal reactions may differ from human responses. Additionally, the LAL test only detects endotoxins, posing a safety risk by overlooking non-endotoxin pyrogens that may be present in the sample. To address these limitations, the monocyte activation test (MAT) was introduced in the European Pharmacopoeia in 2010 as a compendial method to replace the Rabbit Pyrogen Test (EP Chapter 2.6.30) and is specified in FDA guidance for industries. Continuous innovations and developments in MAT assays and reagents by market participants have led to enhancements in reproducibility, sensitivity, and specificity, establishing it as a reliable and safer option for pyrogen detection.

Report Segmentation and ScopeSource-based Insights

By source, the monocyte activation tests market is divided into PMBC and cell line categories. The PMBC segment held a larger market share in 2022 and is expected to maintain this trend during the forecast period, with a higher CAGR anticipated from 2022 to 2030. Currently, there are two commercialized sources of monocyte activation test cells available globally: the Mono-Mac-6 (MM6) cell line and Peripheral Blood Mononuclear Cells (PBMC). The MM6 cell line is derived from the blood of a single patient with acute monocytic leukemia, which can result in monocytes that do not consistently express TLRs necessary for detecting pyrogenic contaminants and triggering cytokine release as would occur in a healthy human. Consequently, the reproducibility of MAT results using this cell source has been found to be low. The Ph. Eur. (2.6.30) also describes MM6-based MAT kits as "limited" in their ability to detect non-endotoxin pyrogens. In contrast, PBMC-based MAT kits utilize PBMC sourced from pooled blood of screened, healthy donors, allowing for a more accurate simulation of human monocyte activation when incubated with a spiked product sample. As a result, MAT kits based on this cell source have consistently demonstrated reproducible results. The Ph. Eur. (2.6.30) recognizes this cell source as proficient in detecting both endotoxins and non-endotoxin pyrogens.

Currently, there are three other commercialized PBMC-based monocyte activation test vendors in the market, each with a limit of detection (LoD) of 0.125 EU/ml, 0.02 EU/ml, and 0.016 EU/ml. The CTL-MAT assay boasts one of the leading market LoDs at 0.004 EU/ml, making it the most sensitive monocyte activation test available globally.

Products-based InsightsIn terms of products, the monocyte activation tests market is divided into MAT kits and reagents. The MAT kits segment held a larger market share in 2022 and is expected to continue this trend during the forecast period, while the reagents segment is projected to experience a higher CAGR during the forecast period.

Application-based InsightsBy application, the monocyte activation tests market is segmented into drug development, vaccine development, medical devices, and others (such as research). The drug development segment captured the largest share in 2022 and is expected to maintain this trend from 2022 to 2030. According to the National Library of Medicine, pharmaceuticals are a group of emerging organic compounds that have significantly improved patients' quality of life. The pharmaceutical sector is involved in the production, development, and marketing of both branded and generic pharmaceuticals. For the first time in 2014, global pharmaceutical revenues surpassed US$ 1 trillion. The pharmaceutical market has been growing at an annual rate of 5.8% since 2017, with worldwide pharmaceutical market revenue reaching US$ 1,143 billion in 2017 and US$ 1,462 billion in 2021. The monocyte activation test (MAT) is designed to evaluate parenteral drugs, biologics, and medical devices for all classifications of pyrogens. Parenteral-administered pharmaceutical products must be free from pyrogenic (fever-inducing) contamination, as these substances can trigger a life-threatening systemic response in the patient's innate immune system. Ensuring that biological products are free from contaminating pyrogenic material before administration to patients is crucial. Initially, the Rabbit Pyrogen Test (RPT) and the Bacterial Endotoxin Test (BET)/Limulus Amebocyte Lysate Assay (LAL) were used as ex-vivo options.

However, stringent regulations regarding animal testing methods have compelled market participants to develop alternative methods that minimize animal use. Given the limitations of the RPT and BET, along with the increasing production of complex products, the European Pharmacopoeia introduced MAT activation testing methods that simulate the human immune response and combine the advantages of the RPT (assessing pyrogenicity beyond gram-negative endotoxin) with the benefits of an in vitro method. Unlike the RPT, MAT can be applied as a fully quantitative test without animal use, making it more suitable for inherently pyrogenic vaccines and physiologically relevant since it utilizes human cells. MAT testing assays can detect blood-derived products, cell-derived products, biologics, and vaccines. The MAT testing methods can also assess a wide range of drug products and medical devices, including those that cannot undergo in vivo testing (for example, products containing hyaluronic acid). These factors have contributed to the overall growth of the monocyte activation tests market in recent years and are expected to continue this trend during the forecast period.

Monocyte Activation Tests Market Report Scope

Regional Analysis

Regionally, the monocyte activation tests market is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. North America held the largest market share in 2022 and is expected to maintain this trend during the forecast period, followed by Europe. Regulatory practices governing monocyte activation tests by organizations such as the United States Pharmacopeia (USP) and the Government of Canada have further stimulated the overall growth of the monocyte activation tests market in the region. Additionally, an increasing focus on patient safety and improved healthcare outcomes is contributing to market growth in North America.

Leading companies in the monocyte activation tests market include Merck KGaA, Darmstadt, Germany and/or its affiliates; Charles River Laboratories International, Inc.; Thermo Fisher Scientific; Sanquin; and Lonza Group.

In October 2023, Lonza introduced two new rapid monocyte activation test (MAT) systems, the PyroCell MAT Rapid System and PyroCell MAT Human Serum (HS) Rapid System, aimed at simplifying and expediting rabbit-free pyrogen testing. These systems will replace Lonza's traditional MAT system kit offerings, and the newly launched products feature the new PeliKine Human IL-6 Rapid ELISA Kit, which reduces hands-on time and shortens time-to-results from two days to two hours. The new tests provide pharmaceutical and biotechnology manufacturers with more accessible MAT testing options for product safety testing while helping to decrease reliance on animal testing.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Monocyte Activation Tests Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Monocyte Activation Tests Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Monocyte Activation Tests Market - Global Market Analysis

  • 6.1 Monocyte Activation Tests - Global Market Overview
  • 6.2 Monocyte Activation Tests - Global Market and Forecast to 2030

7. Monocyte Activation Tests Market - Revenue Analysis (USD Million) - By Source, 2020-2030

  • 7.1 Overview
  • 7.2 PMBC
  • 7.3 Cell Line

8. Monocyte Activation Tests Market - Revenue Analysis (USD Million) - By Products, 2020-2030

  • 8.1 Overview
  • 8.2 MAT Kits
  • 8.3 Reagents

9. Monocyte Activation Tests Market - Revenue Analysis (USD Million) - By Application, 2020-2030

  • 9.1 Overview
  • 9.2 Drug Development
  • 9.3 Vaccine Development
  • 9.4 Medical Devices
  • 9.5 Others (Research etc.)

10. Monocyte Activation Tests Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Monocyte Activation Tests Market Overview
    • 10.1.2 North America Monocyte Activation Tests Market Revenue and Forecasts to 2030
    • 10.1.3 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Source
    • 10.1.4 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Products
    • 10.1.5 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Application
    • 10.1.6 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Monocyte Activation Tests Market
        • 10.1.6.1.1 United States Monocyte Activation Tests Market, by Source
        • 10.1.6.1.2 United States Monocyte Activation Tests Market, by Products
        • 10.1.6.1.3 United States Monocyte Activation Tests Market, by Application
      • 10.1.6.2 Canada Monocyte Activation Tests Market
        • 10.1.6.2.1 Canada Monocyte Activation Tests Market, by Source
        • 10.1.6.2.2 Canada Monocyte Activation Tests Market, by Products
        • 10.1.6.2.3 Canada Monocyte Activation Tests Market, by Application
      • 10.1.6.3 Mexico Monocyte Activation Tests Market
        • 10.1.6.3.1 Mexico Monocyte Activation Tests Market, by Source
        • 10.1.6.3.2 Mexico Monocyte Activation Tests Market, by Products
        • 10.1.6.3.3 Mexico Monocyte Activation Tests Market, by Application
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Pre and Post Covid-19 Impact

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Monocyte Activation Tests Market - Key Company Profiles

  • 14.1 Merck KGaA, Darmstadt,Germany and/or its Affiliates
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Charles River Laboratories International, Inc.
  • 14.3 Thermo Fisher Scientific
  • 14.4 Sanquin
  • 14.5 Lonza Group
  • 14.6 MAT Biotech
  • 14.7 Cellmade Laboratories
  • 14.8 Labor LS SE & Co. KG
  • 14.9 BD Biosciences
  • 14.10 Beckman Coulter

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud